The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute ...

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than ...

The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

A group of experts discusses the use of continuous glucose monitoring (CGM) technology in diabetes and its transformative ...

The longer wear time should improve Dexcom’s margins and help it compete with Abbott, RBC Capital Markets analyst Shagun ...

DexCom stock was on the rise Thursday after the maker of medical technology said it had received clearance from the U.S. Food ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

A new technology for management of diabetes is cost-effective for patients in the US with type 1 diabetes compared with traditional treatments.

Researchers identified 502 blood metabolites linked to prediabetes and type 2 diabetes, with 143 tied to the gut microbiome.

Light doesn’t just travel in straight lines—it can also twist. And when it does, it opens new frontiers in science and medicine. A recent breakthrough led by Professor Igor Meglinski at Aston ...

People live without their pancreas by taking medications and making good lifestyle choices. Learn about treatments and ...